2024-11-12 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

This report provides a comprehensive analysis of Eli Lilly and Co (LLY), a pharmaceutical company developing and manufacturing pharmaceutical products.

**1. Performance Comparison**

LLY has significantly outperformed the S&P 500 (VOO) with a cumulative return of 788.45% compared to VOO's 142.82%. This translates to a substantial 645.63% outperformance, placing LLY in the 80.52 percentile of its historical performance range against VOO.

| Year       | CAGR | MDD  | Alpha | Beta | Market Cap (B) |
|------------|------|------|-------|------|---------------|
| 2015-2017  | 20.6% | 19.6% | -9.6% | 0.8 | 80.18 |
| 2016-2018  | 39.6% | 19.2% | 14.9% | 0.7 | 109.85 |
| 2017-2019  | 76.2% | 17.2% | 33.1% | 0.7 | 124.77 |
| 2018-2020  | 99.4% | 22.1% | 60.3% | 0.7 | 160.28 |
| 2019-2021  | 140.4% | 22.1% | 50.6% | 0.7 | 262.22 |
| 2020-2022  | 176.7% | 22.1% | 159.0% | 0.7 | 347.30 |
| 2021-2023  | 252.2% | 18.6% | 223.4% | 0.5 | 553.38 |
| 2022-2024  | 206.0% | 19.0% | 180.8% | 0.6 | 757.03 |

The table shows LLY's consistent outperformance over VOO.  LLY's Alpha values indicate a positive excess return above the benchmark, further highlighting its strength.

**2. Recent Price Movements**

* **Closing Price:** 831.54 (Last-market: 834.84)
* **5-day Moving Average:** 803.51
* **20-day Moving Average:** 870.46
* **60-day Moving Average:** 904.3

The current price is below all three moving averages, suggesting a potential short-term downtrend.  

**3. Technical Indicators**

* **RSI:** 32.69 - This indicates that LLY is in oversold territory, potentially suggesting a bounce back.
* **PPO:** -0.91 - This suggests that the price momentum is weakening, potentially indicating a downward trend.
* **Delta_Previous_Relative_Divergence:** -14.22 (-) - This indicates a recent short-term downward trend in relative performance. 
* **Expected Return:** 98.39% - This indicates a potential for high long-term returns compared to the S&P 500.

**4. Recent Earnings Performance**

| Date       | EPS | Revenue       |
|------------|-----|---------------|
| 2024-10-30 | 1.08 | 11.44 B$     |
| 2024-08-08 | 3.29 | 11.30 B$     |
| 2024-04-30 | 2.49 | 8.77 B$      |
| 2023-11-02 | -0.06 | 9.50 B$      |
| 2024-10-30 | -0.06 | 9.50 B$      |

**5. Financial Information**

**1) Revenue and Profitability**

| Quarter      | Revenue       | Profit Margin |
|--------------|---------------|---------------|
| 2024-09-30  | $11.44B     | 81.02%       |
| 2024-06-30  | $11.30B     | 80.80%       |
| 2024-03-31   | $8.77B      | 80.91%       |
| 2023-12-31   | $9.35B      | 80.88%       |
| 2023-09-30   | $9.50B      | 80.42%       |

**2) Capital and Profitability**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2024-09-30  | $14.24B  | 6.81%   |
| 2024-06-30  | $13.56B  | 21.88%  |
| 2024-03-31   | $12.81B  | 17.51%  |
| 2023-12-31   | $10.77B  | 20.33%  |
| 2023-09-30   | $11.22B  | -0.51%  |

**6. News and Recent Issues**

* **Recent Earnings:** LLY's recent earnings release was positive, with the company beating both EPS and revenue expectations.
* **Recent Market Outlook:**  The market outlook for LLY remains positive due to its strong fundamentals and expected growth in key areas like diabetes treatments and oncology. 
* **Analyst Opinions:**  Many analysts recommend buying LLY stock, citing its strong earnings, innovation pipeline, and long-term growth potential.  
* **Performance Highlights:**  LLY has consistently outperformed its peers in recent years, driven by its robust product portfolio and successful drug launches.

**7. Overall Analysis**

LLY has demonstrated strong historical performance, outperforming the S&P 500 significantly. Recent earnings and financial indicators suggest continued strong profitability and potential for growth.  While the current market environment is somewhat volatile, the stock is in oversold territory and could be considered an attractive investment opportunity for long-term investors seeking exposure to the healthcare sector.  

**8. Recommendations**

Based on the above analysis, LLY appears to be a compelling investment option for long-term investors seeking a well-established and innovative pharmaceutical company with a strong track record of success. 
